Targeting RIPK3 in Flu-Associated Lung Injury
靶向 RIPK3 治疗流感相关肺损伤
基本信息
- 批准号:10020307
- 负责人:
- 金额:$ 67.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-18 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdult Respiratory Distress SyndromeAffectAnimalsAntiviral AgentsApoptosisAreaAvian Influenza A VirusBacterial PneumoniaBindingBiochemistryBiological AssayBirdsCell DeathCell Death Signaling ProcessCellsCessation of lifeChronicClinicalClinical TrialsComplexCrystallizationDataDiseaseDistalDrug KineticsEpithelialEpitheliumGoalsHospitalizationHumanIn VitroInfectionInflammationInflammatoryInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H5N1 SubtypeInfluenza A virusInjuryLaboratoriesLeadLungLung InflammationLung diseasesLytic VirusMediatingMediator of activation proteinModelingMolecular ConformationMolecular TargetMorbidity - disease rateMusMutationNecrosisPathogenicityPathologyPathway interactionsPharmaceutical ChemistryPhosphotransferasesPneumococcal PneumoniaPneumoniaPre-Clinical ModelProteinsPyrimidineRIPK3 geneRegimenReportingResearch PersonnelRheumatoid ArthritisSafetySeriesSignal PathwayStructureStructure-Activity RelationshipSystemic Inflammatory Response SyndromeTNF geneTestingTherapeuticToxic effectTreatment EfficacyVaccinesViralViral PathogenesisViral PneumoniaVirulentVirusVirus Diseasesairway epitheliumanalogappropriate dosebasecell typeclinically relevantdrug discoveryflugenomic RNAhigh riskimprovedin vivoin vivo Modelinhibitor/antagonistkinase inhibitorlung injurymortalitymouse modelnovel therapeuticspandemic diseasepandemic influenzaprogramsscaffoldseasonal influenzasensorsmall moleculetherapeutic developmenttherapeutic evaluationtherapeutic targettreatment strategyviral resistance
项目摘要
PROJECT SUMMARY/ABSTRACT
Seasonal influenza A virus (IAV) infections account for over 700,000 hospitalizations and 50,000 annual deaths
in the US alone. Moreover, highly virulent H5 and H7 strains of avian IAV, while currently limited in their spread
between humans, are only a few mutations from acquiring the capacity for widespread transmissibility. As
current vaccines and antiviral strategies are either limited in their efficacy or susceptible to viral resistance and
evasion, identifying new therapeutic entry-points for seasonal and virulent IAV disease, preferably those that
target pathogenic host signaling pathways, is an urgent imperative. We have identified the host kinase RIPK3
as a promising new entry point for therapeutic development against IAV. RIPK3 is the central mediator of a
highly pro-inflammatory form of cell death termed necroptosis, which we have found is a major contributor to
lung injury and inflammation during IAV infection. Both seasonal and pandemic strains of IAV trigger RIPK3-
dependent necrotic lung damage that we propose underlies Acute Respiratory Distress Syndrome (ARDS), as
well as viral and bacterial pneumonia, each of which remain major causes of morbidity and mortality following
IAV infection. Notably, RIPK3 also mediates or amplifies a range of chronic TNF-α-mediated pathologies (such
as rheumatoid arthritis) making it a very attractive new molecular target for multiple inflammatory conditions.
Curiously, given how important a therapeutic target RIPK3 potentially is, no selective RIPK3 inhibitors have
been advanced into clinical trials. We now have developed a new structural class of RIPK3 inhibitor, which we
call the UH15 series, and which is based on a pyrido[2,3-d]pyrimidine scaffold that targets both the ATP- as
well as the allosteric Glu-out pockets of RIPK3. Our preliminary findings reveal that UH15 analogs, after just
one round of optimization, are already more potent than current RIPK3 inhibitors and display promising activity
against IAV induced necrosis in vitro and in vivo. These exciting results highlight the immediate translational
potential of the UH15 series for necrotic lung injury and consequent ARDS and pneumonia triggered by
seasonal and virulent strains of IAV. The goals of our proposal are to iteratively optimize UH15-based
compounds for RIPK3 blockade in vitro and, by use of a rapid mouse model of RIPK3-mediated pathology (the
TNF SIRS model), prioritize compounds for use in vivo (Aim 1). We then propose to assess these UH15
compounds for therapeutic efficacy in a variety of IAV-triggered disease settings, including the scenarios of (1)
high-risk seasonal IAV infections, (2) infection by highly pathogenic avian IAV, and (3) secondary pneumococcal
pneumonia following seasonal IAV infection (Aim 2). The proposed studies bring together a team of researchers
with strong, complementary expertise in small-molecule medicinal chemistry (Cuny), RIPK3 kinase biochemistry
and function in inflammation (Degterev), and RIPK3-mediated cell death signaling during IAV pathogenesis
(Balachandran, Thomas). Successful completion of these Aims has the potential to transform the treatment of
multiple IAV-induced diseases initiated or amplified by necrotic lung injury.
项目摘要/摘要
季节性甲型流感病毒(IAV)感染每年导致70多万人住院和5万人死亡
仅在美国。此外,高毒力的H5和H7禽流感病毒株目前传播有限
在人类之间,只有少数几个突变才能获得广泛传播的能力。AS
目前的疫苗和抗病毒策略要么疗效有限,要么容易产生病毒耐药性,
逃避,为季节性和致命性IAV疾病确定新的治疗切入点,最好是那些
靶向致病宿主信号通路,是当务之急。我们已经鉴定了宿主激酶RIPK3
作为针对IAV的治疗开发的一个有前途的新切入点。RIPK3是
高度促炎的细胞死亡形式称为坏死性下垂,我们发现它是导致
IAV感染时的肺损伤和炎症。季节性和大流行的IAV毒株都会触发RIPK3-
我们提出的依赖性坏死性肺损伤是急性呼吸窘迫综合征(ARDS)的基础,AS
以及病毒性肺炎和细菌性肺炎,每一种肺炎都是以下疾病的主要致病和死亡原因
IAV感染。值得注意的是,RIPK3还介导或放大了一系列慢性肿瘤坏死因子-α介导的病理(如
如类风湿性关节炎),使其成为治疗多种炎症条件的非常有吸引力的新分子靶点。
奇怪的是,考虑到RIPK3潜在的治疗靶点是多么重要,没有选择性的RIPK3抑制剂
已进入临床试验阶段。我们现在已经开发出一种新的RIPK3抑制剂的结构类别,我们
称为UH15系列,它基于以ATP-AS为靶点的吡啶[2,3-d]嘧啶支架
以及RIPK3的变构Glu-out口袋。我们的初步发现显示,UH15类似物,在刚刚
一轮优化,已经比目前的RIPK3抑制剂更有效,并显示出良好的活性
体外和体内抗IAV诱导的坏死。这些令人兴奋的结果突出了即时的翻译
UH15系列对坏死性肺损伤以及由此引发的ARDS和肺炎的潜在作用
季节性和强毒的IAV株。我们提案的目标是迭代优化基于UH15的
化合物在体外阻断RIPK3,并通过使用RIPK3介导的病理的快速小鼠模型(
肿瘤坏死因子SIRS模型),对体内使用的化合物进行优先排序(目标1)。然后,我们建议评估这些UH15
化合物在各种IAV引发的疾病环境中的治疗效果,包括(1)
高危季节性IAV感染,(2)高致病性禽类IAV感染,(3)继发性肺炎球菌
季节性IAV感染后肺炎(目标2)。拟议的研究将一组研究人员聚集在一起
在小分子药物化学(CUNY)方面拥有强大的互补专业知识,RIPK3激酶生物化学
和炎症中的功能(Degterev),以及在IAV致病过程中RIPK3介导的细胞死亡信号
(托马斯·巴拉钱德兰)。这些目标的成功完成有可能改变治疗
由坏死性肺损伤引发或放大的多种IAV诱发的疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SIDDHARTH BALACHANDRAN其他文献
SIDDHARTH BALACHANDRAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SIDDHARTH BALACHANDRAN', 18)}}的其他基金
Small-molecule exploitation of ZBP1-driven nuclear necroptosis for cancer immunotherapy
ZBP1 驱动的核坏死性凋亡的小分子开发用于癌症免疫治疗
- 批准号:
10586659 - 财政年份:2023
- 资助金额:
$ 67.89万 - 项目类别:
Harnessing ZBP1-triggered cell death to enhance influenza vaccine responsiveness
利用 ZBP1 触发的细胞死亡来增强流感疫苗的反应性
- 批准号:
10884586 - 财政年份:2023
- 资助金额:
$ 67.89万 - 项目类别:
Role of ZBP1 in pathogenesis of Salmonella biofilms
ZBP1 在沙门氏菌生物膜发病机制中的作用
- 批准号:
10658383 - 财政年份:2023
- 资助金额:
$ 67.89万 - 项目类别:
Necroptosis in SARS-CoV-2 pathogenesis, evolution, and therapy
SARS-CoV-2 发病机制、进化和治疗中的坏死性凋亡
- 批准号:
10433040 - 财政年份:2022
- 资助金额:
$ 67.89万 - 项目类别:
Necroptosis in SARS-CoV-2 pathogenesis, evolution, and therapy
SARS-CoV-2 发病机制、进化和治疗中的坏死性凋亡
- 批准号:
10557863 - 财政年份:2022
- 资助金额:
$ 67.89万 - 项目类别:
Harnessing ZBP1-driven cell death to improve influenza vaccine efficacy
利用 ZBP1 驱动的细胞死亡来提高流感疫苗的功效
- 批准号:
10455196 - 财政年份:2021
- 资助金额:
$ 67.89万 - 项目类别:
Targeting RIPK3 in Flu-Associated Lung Injury
靶向 RIPK3 治疗流感相关肺损伤
- 批准号:
10470746 - 财政年份:2019
- 资助金额:
$ 67.89万 - 项目类别:
Targeting RIPK3 in Flu-Associated Lung Injury
靶向 RIPK3 治疗流感相关肺损伤
- 批准号:
10689229 - 财政年份:2019
- 资助金额:
$ 67.89万 - 项目类别:
Targeting RIPK3 in Flu-Associated Lung Injury
靶向 RIPK3 治疗流感相关肺损伤
- 批准号:
10238084 - 财政年份:2019
- 资助金额:
$ 67.89万 - 项目类别:
Mechanism, Function, and Exploitation of Influenza A Virus-Activated Cell Death
甲型流感病毒激活的细胞死亡的机制、功能和利用
- 批准号:
10247652 - 财政年份:2017
- 资助金额:
$ 67.89万 - 项目类别:
相似海外基金
CLINICAL MODELS OF THE ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的临床模型
- 批准号:
6564818 - 财政年份:2001
- 资助金额:
$ 67.89万 - 项目类别:
ADHESION MOLECULES IN ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征中的粘附分子
- 批准号:
6410976 - 财政年份:2000
- 资助金额:
$ 67.89万 - 项目类别:
TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的治疗
- 批准号:
6370267 - 财政年份:2000
- 资助金额:
$ 67.89万 - 项目类别:
CLINICAL MODELS OF THE ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的临床模型
- 批准号:
6418789 - 财政年份:2000
- 资助金额:
$ 67.89万 - 项目类别:
TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的治疗
- 批准号:
6370266 - 财政年份:2000
- 资助金额:
$ 67.89万 - 项目类别:
TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的治疗
- 批准号:
6370265 - 财政年份:2000
- 资助金额:
$ 67.89万 - 项目类别:
CLINICAL MODELS OF THE ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的临床模型
- 批准号:
6302122 - 财政年份:1999
- 资助金额:
$ 67.89万 - 项目类别:
ADHESION MOLECULES IN ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征中的粘附分子
- 批准号:
6309780 - 财政年份:1999
- 资助金额:
$ 67.89万 - 项目类别:
CLINICAL MODELS OF THE ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的临床模型
- 批准号:
6109540 - 财政年份:1998
- 资助金额:
$ 67.89万 - 项目类别:
ADHESION MOLECULES IN ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征中的粘附分子
- 批准号:
6265845 - 财政年份:1998
- 资助金额:
$ 67.89万 - 项目类别: